The UK remains committed to alleviating the suffering of children globally, including in the Occupied Palestinian Territories. In Gaza, where an estimated 40,000 children suffer from micronutrient deficiencies, we recently provided a further £2 million for UN Children\u2019s Fund (UNICEF) which will help to address some of the underlying causes of malnutrition by helping to improve the quality of water available to the entire population of Gaza.<\/p>
<\/p>
To help address needs in Area C, the UK has allocated £1.1 million to support essential infrastructure for vulnerable Palestinians. We are supporting 4 communities comprising of nearly 500 Palestinian families living in Area C to remain on their land through improved infrastructure and access to community services, including education and health.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1201", "label" : {"_value" : "Biography information for Alistair Burt"} } , "answeringMemberConstituency" : {"_value" : "North East Bedfordshire"} , "answeringMemberPrinted" : {"_value" : "Alistair Burt"} , "dateOfAnswer" : {"_value" : "2018-11-19", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-19T16:56:37.227Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "20"} , "answeringDeptShortName" : {"_value" : "International Development"} , "answeringDeptSortName" : {"_value" : "International Development"} , "date" : {"_value" : "2018-11-14", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Palestinians: Children"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for International Development, what assessment her Department has made of levels of (a) stunting and (b) malnutrition in (i) Palestinian children in Gaza and (ii) Bedouin children in Area C of the West Bank.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4523", "label" : {"_value" : "Biography information for Catherine West"} } , "tablingMemberConstituency" : {"_value" : "Hornsey and Wood Green"} , "tablingMemberPrinted" : [{"_value" : "Catherine West"} ], "uin" : "191447"} , {"_about" : "http://data.parliament.uk/resources/1005714", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1005714/answer", "answerText" : {"_value" : "
NHS England has considered a policy for Kuvan (sapropterin) at the Clinical Priorities Advisory Group (CPAG) meeting on 6/7 November. Whilst NHS England did make an estimate of the current cost of protein supplements and a potential reduction in their use if Kuvan were prescribed, this cost was not included in the analysis because commissioning responsibility for supplements rests with clinical commissioning groups and it would be unlikely that NHS England would be able to realise these savings. The cost of the potential reduction in protein supplements is also relatively modest compared to the cost of Kuvan.<\/p>
<\/p>
In line with its published process, the recommendations from CPAG will be considered by the Specialised Commissioning Oversight Group and the Specialised Services Commissioning Committee. A decision about whether or not Kuvan has been prioritised for funding will be published in due course.<\/p>
<\/p>
The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of Kuvan for the treatment of phenylketonuria. In developing technology appraisal guidance, NICE takes into account all the health and publicly funded social care related costs and benefits associated with the treatment, potentially including any costs from NHS funded treatments that can be avoided such as food supplements. The NICE appraisal of Kuvan is now underway and NICE expects to publish final guidance next year.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-11-20", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "190519"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-20T15:25:36.617Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-11-12", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Sapropterin"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to NHS England\u2019s appraisal of Kuvan, what steps his Department is taking to ensure that the cost offset of dietary treatments is considered in its economic assessment of the cost of commissioning new medicines.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4523", "label" : {"_value" : "Biography information for Catherine West"} } , "tablingMemberConstituency" : {"_value" : "Hornsey and Wood Green"} , "tablingMemberPrinted" : [{"_value" : "Catherine West"} ], "uin" : "190518"} , {"_about" : "http://data.parliament.uk/resources/1005715", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1005715/answer", "answerText" : {"_value" : "
NHS England has considered a policy for Kuvan (sapropterin) at the Clinical Priorities Advisory Group (CPAG) meeting on 6/7 November. Whilst NHS England did make an estimate of the current cost of protein supplements and a potential reduction in their use if Kuvan were prescribed, this cost was not included in the analysis because commissioning responsibility for supplements rests with clinical commissioning groups and it would be unlikely that NHS England would be able to realise these savings. The cost of the potential reduction in protein supplements is also relatively modest compared to the cost of Kuvan.<\/p>
<\/p>
In line with its published process, the recommendations from CPAG will be considered by the Specialised Commissioning Oversight Group and the Specialised Services Commissioning Committee. A decision about whether or not Kuvan has been prioritised for funding will be published in due course.<\/p>
<\/p>
The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of Kuvan for the treatment of phenylketonuria. In developing technology appraisal guidance, NICE takes into account all the health and publicly funded social care related costs and benefits associated with the treatment, potentially including any costs from NHS funded treatments that can be avoided such as food supplements. The NICE appraisal of Kuvan is now underway and NICE expects to publish final guidance next year.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-11-20", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "190518"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-20T15:25:36.67Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-11-12", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Sapropterin"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the financial cost offset to the NHS including savings to the NHS from reduced acquisition costs of food supplements of commissioning Kuvan for the treatment of phenylketonuria.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4523", "label" : {"_value" : "Biography information for Catherine West"} } , "tablingMemberConstituency" : {"_value" : "Hornsey and Wood Green"} , "tablingMemberPrinted" : [{"_value" : "Catherine West"} ], "uin" : "190519"} , {"_about" : "http://data.parliament.uk/resources/1005716", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1005716/answer", "answerText" : {"_value" : "
Medicines and other treatments being considered for assessment by the National Institute for Health and Care Excellence (NICE) are considered through an established topic selection process to ensure that they are suitable for referral to NICE and that they are routed to the most appropriate process within NICE. The topic selection process includes consideration of topic against published criteria and consultation with stakeholders. Most new medicines are referred for assessment through NICE\u2019s technology appraisal programme though NICE also operates a separate highly specialised technology evaluation programme for a small number of very high cost drugs for the treatment of very rare diseases. Following consideration through the topic selection process, NICE is currently developing guidance on two drugs for the treatment of phenylketonuria through its technology appraisal programme.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-11-20", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-20T15:26:35.197Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-11-12", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Rare Diseases: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether a single technology appraisal process or a highly specialised technology appraisal process is used for (a) phenylketonuria and (b) other rare diseases.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4523", "label" : {"_value" : "Biography information for Catherine West"} } , "tablingMemberConstituency" : {"_value" : "Hornsey and Wood Green"} , "tablingMemberPrinted" : [{"_value" : "Catherine West"} ], "uin" : "190520"} , {"_about" : "http://data.parliament.uk/resources/1005873", "AnsweringBody" : [{"_value" : "Department for Transport"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1005873/answer", "answerText" : {"_value" : "
The Crossrail 2 Independent Affordability Review, chaired by Mike Gerrard, has provided interim recommendations to the Secretary of State for Transport and Mayor of London this summer, including recommendations for further work to ensure the scheme taken forward is affordable. This further work is now being taken forward to inform the next steps for the project, including looking at route options, and to subsequently complete and finalise the Review.<\/p>
<\/p>
Following the additional work, we expect to publish the findings of the Gerrard Review in due course.<\/p>
<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3996", "label" : {"_value" : "Biography information for Andrew Jones"} } , "answeringMemberConstituency" : {"_value" : "Harrogate and Knaresborough"} , "answeringMemberPrinted" : {"_value" : "Andrew Jones"} , "dateOfAnswer" : {"_value" : "2018-11-15", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-15T11:36:30.327Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "27"} , "answeringDeptShortName" : {"_value" : "Transport"} , "answeringDeptSortName" : {"_value" : "Transport"} , "date" : {"_value" : "2018-11-12", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Crossrail 2 Line"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Transport, what progress has been made on confirming the final proposed route for Crossrail 2.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4523", "label" : {"_value" : "Biography information for Catherine West"} } , "tablingMemberConstituency" : {"_value" : "Hornsey and Wood Green"} , "tablingMemberPrinted" : [{"_value" : "Catherine West"} ], "uin" : "190562"} , {"_about" : "http://data.parliament.uk/resources/1003616", "AnsweringBody" : [{"_value" : "Treasury"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1003616/answer", "answerText" : {"_value" : "
Treasury Ministers have meetings with a variety of public and private organisations, including the Bank of England, as part of the process of policy development.<\/p>
<\/p>
Details of ministerial meetings with external organisations are published quarterly at: https://www.gov.uk/government/collections/hmt-ministers-meetings-hospitality-gifts-and-overseas-travel<\/a><\/p> <\/p> Green Finance is an important area of collaboration with the Bank of England, and we welcome the Bank\u2019s recent announcement to set out, for consultation, supervisory expectations for banks and insurers to consider climate risks in their approach.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4051", "label" : {"_value" : "Biography information for John Glen"}
}
, "answeringMemberConstituency" : {"_value" : "Salisbury"}
, "answeringMemberPrinted" : {"_value" : "John Glen"}
, "dateOfAnswer" : {"_value" : "2018-11-19", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "189843"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-11-19T16:10:52.057Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "14"}
, "answeringDeptShortName" : {"_value" : "Treasury"}
, "answeringDeptSortName" : {"_value" : "Treasury"}
, "date" : {"_value" : "2018-11-09", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Financial Services: Climate Change"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Chancellor of the Exchequer, what discussions he has had with the Governor of the Bank of England on managing the risk to the financial system posed by climate change.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4523", "label" : {"_value" : "Biography information for Catherine West"}
}
, "tablingMemberConstituency" : {"_value" : "Hornsey and Wood Green"}
, "tablingMemberPrinted" : [{"_value" : "Catherine West"}
], "uin" : "189774"}
, {"_about" : "http://data.parliament.uk/resources/1003617", "AnsweringBody" : [{"_value" : "Treasury"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1003617/answer", "answerText" : {"_value" : " Treasury Ministers have meetings with a variety of public and private organisations, including the Bank of England, as part of the process of policy development.<\/p> <\/p>